Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study

Revista de Investigacion Clinica

Volumn 64, Issue 4, 2012, Pages 315-321

  Reyes Marín, Fernando Arturo ^a   Calzada, Claudia ^c   Ballesteros, Araceli ^a   Amato, Dante ^b  

^a Hospital de Concentración   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

ACE inhibitors; Angiotensin II blockers; Automated peritoneal dialysis; Randomized controlled trial; Residual renal function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENALAPRIL; LOSARTAN; PRAZOSIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTOMATED PERITONEAL DIALYSIS; AUTOMATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COUGHING; COURSE EVALUATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PERITONITIS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RESIDUAL RENAL FUNCTION; SIDE EFFECT; URINALYSIS; URINE VOLUME;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; CREATININE; DISEASE PROGRESSION; ENALAPRIL; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; UREA; YOUNG ADULT;

EID: 84869825331     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: 1-290.
2. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
3. Ruggenenti P, Perna A, Gherardi G, Garini G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64. (Pubitemid 29355751)
4. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1: 1054-65.
5. Wolf G, Neilson EG. Angiotensin-II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-40.
6. Fern RJ, Yesko CM, Thornhill BA, et al. Reduced angiotensin expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999; 103: 39-46. (Pubitemid 29031161)
7. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin-II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7. (Pubitemid 24177156)
8. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
9. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62. (Pubitemid 23335891)
10. Kalaitzidis RG, Bakris GL. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep 2009; 11: 436-42.
11. Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: A critical review. Am J Kidney Dis 2009; 53: 1068-81.
12. Lewis E, Hunsicker L, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
13. Moist LM, Port FK, Orzol Sm, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-64. (Pubitemid 30115086)
14. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2008; 23: 3704-10.
15. Li PKT, Chow KM, Wong TYH, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann Intern Med 2003; 139: 105-12.
16. Suzuki H, Kanno Y, Sugahora S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056-64. (Pubitemid 38691501)
17. Wank AY-M, Lai K-N. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69: 1726-32. (Pubitemid 43739198)
18. Kolesnyk I, Noordzij M, Dekker FW, et al. Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Perit Dial Int 2011; 31: 53-9.
19. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 307-20.
20. Reyes Marin A, Asbun J, Amato D. Efectividad de hemodiálisis diaria comparada con hemodiálisis intermitente en el tratamiento por insuficiencia renal aguda. Nefrología Mexicana 2011; 32: 3-7.
21. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-88. (Pubitemid 30070837)
22. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7. (Pubitemid 24177156)
23. Bro S, Bjorner JB, Tofte-Jensen P, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19: 526-33. (Pubitemid 30015565)
24. De Fijter CW, Oe LP, Nauta JJ, et al. Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis. Ann Intern Med 1994; 120: 264-71. (Pubitemid 24050021)
25. Mehrotra R. Long-term outcomes in automated peritoneal dialysis: Similar or better than in continuous ambulatory peritoneal dialysis? Perit Dial Int 2009; 29(Suppl. 2): S111-S114.
26. Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology 2003; 8: 184-91. (Pubitemid 36995088)
27. Wieneke MM, Marrion V, Dian CG, et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6; 537-42.
28. Peter G, Blake, Joanne M. Bargman, K Scott Brimble, et al. Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011. Peritoneal Dialysis International 2011; 31: 218-39.